This year’s BIO-CEO conference included a well-attended RNAi panel discussion, featuring the heads of several RNAi therapeutics firms, entitled: “What’s All the Fuss about RNAi?” Although it remains uncertain whether the participants’ presentations — which, for the most part, amounted to corporate overviews well-suited to an audience unfamiliar with RNAi — helped answer this question, they did provide a few new details about each company’s ongoing activities.